demonstrate induction of disease relevant HSPs, including HSP70 and BiP, and enhanced maturation of GCase primary in fibroblasts from GD patients with varied GBA1 mutations subjected to arimoclomol treatment. GCase activity was enhanced in a time and dose-dependent manner in response to arimoclomol treatment, co-occuring with HSP70 induction. Analysis of cellular localization of mutated GCase further indicated lysosomal localization of mutant protein following arimoclomol treatment in both non-neuropathic and neuronopathic patient derived cells. In order to evaluate the effects of arimoclomol in a human neuron-like cell model of GD, multipotent adult stem cells were collected from healthy and neuonopathic and non-neuronopathic GD patient donors and induced toward neural differentiation prior to treatment with arimoclomol or vehicle. Similar to observations in fibroblast cultures, arimoclomol treatment correlated with enhanced GCase activity in patient derived cells.
In brief, these results bolster consideration of the HSP amplifier arimoclomol for development toward the treatment of nonneuronopathic and neuronopathic GD. The status of arimoclomol as the subject of ongoing phase II/III clinical trials for Niemann-Pick disease type C (ClinicalTrials.gov identifier NCT02612129) enhance the drug's attractiveness and give credence to the supposition of activity within the CNS in vivo. However, a more thorough description of the cellular and in vivo effects of arimoclomol would enhance the argument for development toward implementation as a GD therapy. Data presented by Kirkegaard and colleagues suggest that amplification of HSPs underlie the drugs' impact on GCase activity, and as RNAi studies did not result in enough HSP knock-down to be conclusive, future loss-of-function studies conducted with HSP70 family member knock-out cells could be considered to strengthen this hypothesis. The authors demonstrate that arimoclomol increased the activity of mutant GCase up to 50-100% but this increase does not bring GCase activity to levels comparable with that observed in wild type cells, although longer exposures provided additional increases in GCase activity. Interestingly, the differences in GCase activity levels between type III neuronopathic patients and type I non-neuronopathic patients, suggest that increase in the 50-100% would lift the type III activity levels to that of neurologically unaffected type I patients [7] . This might suggest a particular potential for arimoclomol in neuronopathic Gaucher disease. Further clarification of the relative contributions of arimoclomol's effects upon increased GCase catalytic activity and lysosomal delivery to the overall therapeutic impact will be valuable to advancement of drug applications.
Additionally, accumulation of sphingolipids is a hallmark of the cellular phenotype of GD and elucidation of the effect of arimoclomol upon GCase substrate content in GD cells would be a useful indicator of potential therapeutic utility.
Overall, the data from these cell-based assays are promising and one might consider confirming the therapeutic effects of arimoclomol in vivo with GD animal models, such as mice with GCase mutations or ovalalbumin (OVA)-challenged progranulin (PGRN) deficient mice [8] . However, extrapolation of in vivo results from murine models of GD should be interpreted with some degree of trepidation given the discrepancy between human and mouse phenotypes of specific GD mutations [9] . Importantly, in light of PGRN's association with GD and functionality as a co-chaperone of HSP70 during GCase trafficking, the utilization of PGRN-deficient mice, which exhibit a GD-like phenotype upon challenge with OVA, may be particularly interesting and offer novel insights into GD pathogenesis and arimoclomol function [5, 8, 10] .
Neuronopathic GD is a devastating condition for which no effective treatment is currently available. The complex network of molecules implicated in regulation of GD has complicated development of disease modifying drugs but chaperone therapy has received steadily growing acknowledgment as a potential avenue for addressing both peripheral and neuronal GD progression. Continued evaluation of pharmaceuticals targeting key proteostasis mediators, like arimoclomol, could lead to development of novel drugs for the treatment of neuronopathic GD, as well as additional LSDs.
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